EMBEDA Drug Patent Profile

When do Embeda patents expire, and what generic alternatives are available?

Embeda is a drug marketed by Alpharma Pharms and is included in one NDA. There are seven patents protecting this drug and four Paragraph IV challenges.

This drug has seventy-four patent family members in twenty-three countries.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this compound. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Embeda

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 19, 2027. This may change due to patent challenges or generic licensing.

There are four Paragraph IV patent challenges for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for EMBEDA

International Patents:	74
US Patents:	7
Applicants:	1
NDAs:	1
Clinical Trials:	7
Drug Prices:	Drug price information for EMBEDA
What excipients (inactive ingredients) are in EMBEDA?	EMBEDA excipients list
DailyMed Link:	EMBEDA at DailyMed

See drug prices for EMBEDA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for EMBEDA

Constraining patent/regulatory exclusivity:

8,846,104

NDA:

022321

Dosage:

CAPSULE, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for EMBEDA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pfizer	Phase 1
Pfizer	Phase 4
Pfizer	Phase 3

See all EMBEDA clinical trials

Paragraph IV (Patent) Challenges for EMBEDA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	20 mg/0.8 mg	022321	1	2018-08-16
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	30 mg/1.2 mg 50 mg/2 mg 80 mg/3.2 mg	022321	1	2010-05-28
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	60 mg/2.4 mg	022321	1	2010-05-25
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	100 mg/4 mg	022321	1	2010-05-03

US Patents and Regulatory Information for EMBEDA

EMBEDA is protected by seven US patents.

This potential generic entry date is based on patent 8,846,104.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-006	Aug 13, 2009		DISCN	Yes	No	8,846,104		Y
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-005	Aug 13, 2009		DISCN	Yes	No	7,815,934		Y
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-004	Aug 13, 2009		DISCN	Yes	No	7,815,934		Y
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-005	Aug 13, 2009		DISCN	Yes	No	8,877,247		Y
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-005	Aug 13, 2009		DISCN	Yes	No	7,682,633

Expired US Patents for EMBEDA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-005	Aug 13, 2009	8,685,444
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-005	Aug 13, 2009	5,202,128
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-004	Aug 13, 2009	5,202,128
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-005	Aug 13, 2009	5,378,474
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-001	Aug 13, 2009	5,202,128

International Patents for EMBEDA

When does loss-of-exclusivity occur for EMBEDA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Austria

Brazil

Canada

China

Cyprus

Denmark

European Patent Office

Hong Kong

Hungary

Israel

Japan

Mexico

New Zealand

Poland

Portugal

Russian Federation

Slovenia

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EMBEDA around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	154296	Sustained release pharmaceutical composition
Portugal	2526932
China	101677963
Poland	2526932
Russian Federation	2445077	ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ (PHARMACEUTICAL COMPOSITIONS)

Market Dynamics and Financial Trajectory for EMBEDA (Morphine Sulfate and Naltrexone Hydrochloride Extended-Release Capsules)

Last updated: March 4, 2026

What is the current market position of EMBEDA?

EMBEDA, developed by Purdue Pharma, is an extended-release opioid analgesic combining morphine sulfate with naltrexone hydrochloride. Launched in 2010, it targets pain management in patients requiring around-the-clock relief. The drug operates in a high-demand segment but faces a complex landscape due to regulatory and legal pressures surrounding opioids.

What are primary market drivers influencing EMBEDA?

The following factors shape EMBEDA’s market:

• Chronic pain prevalence: An aging population and rising cases of chronic pain drive demand. The CDC reports over 50 million US adults experience daily pain, fueling opioid product use.
• Extended-release formulations: Patients and clinicians prefer formulations with a lower dosing frequency, which is associated with EMBEDA’s extended-release profile.
• Regulatory environment: US drug enforcement agencies and FDA scrutiny have tightened, impacting opioid sales. The risk of abuse and diversion influences prescribing patterns.

How does competition impact EMBEDA?

EMBEDA competes with both opioid and non-opioid analgesics, including:

• Other extended-release opioids: OxyContin (oxycodone ER), MS Contin (morphine ER), and newer formulations like Xtampza ER.
• Non-opioid alternatives: NSAIDs and adjuvant therapies, which are less regulated but often less effective for severe pain.

The opioid market has seen a decline in new prescriptions since 2017, with a 22% decrease observed between 2017 and 2021 in the US, aligning with increased regulatory restrictions.

What are regulatory and legal considerations?

Following the opioid epidemic, regulators have imposed tighter controls:

• FDA warnings: Concerns over addiction and overdose prompted the FDA to issue REMS (Risk Evaluation and Mitigation Strategies) for opioids.
• Legal actions: Purdue Pharma filed for bankruptcy in 2019 amid thousands of lawsuits. These actions threaten product availability and influence market perception.
• Reformulation efforts: Development of abuse-deterrent formulations limits misuse but can increase R&D costs and time to market.

What is the financial trajectory of EMBEDA?

Financial data for EMBEDA is limited as Purdue Pharma filed for bankruptcy in 2019, and the drug’s market share has declined post-litigation.

• Sales figures: Estimated peak US sales ranged between $150 million and $200 million annually in the early 2010s.
• Market decline: Post-2017, sales sharply decreased, aligned with decreased prescriptions and regulatory influences.
• Patent and exclusivity: Embeda’s patent protection expired in 2017, exposing it to generic competition.
• Impact of litigation: Ongoing lawsuits have led to suspension of marketing efforts in some regions and discontinuation in others.

What are future market prospects?

The outlook for EMBEDA includes:

• Market contraction: The opioid epidemic's regulatory fallout limits future growth.
• Potential niche use: Some prescribers may still prescribe for specific, carefully managed cases.
• Alternative therapies: Growth in non-opioid pain management reduces dependence on classical opioids.

How does EMBEDA compare financially with similar drugs?

Drug	Peak US Sales	Market Share (2013-2016)	Patent Status	Status
EMBEDA	$150 million - $200 million	Declined post-2017	Expired 2017	Market share reduced / Generic available
OxyContin	$3 billion (peak)	Dominant (pre-2010s)	Patent expired in 2013	Significant decline post-2010s
MS Contin	$870 million (peak)	Stable early 2000s	Patent expired in 2007	Primary generic now

Key barriers impacting EMBEDA's financial outlook

• Legal risks: Ongoing litigation and lawsuits threaten revenue streams.
• Market saturation: The rise of abuse-deterrent formulations and alternative therapies diminish market share.
• Regulatory restrictions: Risks of future restrictions could further limit prescribing and sales.

Key Takeaways

• EMBEDA faced peak US sales of approximately $200 million pre-2017.
• Patent expiration and legal actions resulted in declining revenues.
• The opioid market's regulatory environment limits growth prospects.
• Competition from abuse-deterrent formulations and alternative therapies intensifies.
• Market contraction is expected to continue due to legal, regulatory, and societal shifts.

FAQs

1. What is the primary therapeutic indication for EMBEDA?
Management of severe pain requiring continuous, around-the-clock opioid therapy.

2. How has legal action impacted EMBEDA’s market presence?
Litigation has led to market withdrawals in some regions and hindered marketing efforts, reducing sales and market share.

3. Does EMBEDA have patent protection remaining?
No; its patent expired in 2017, leading to generic competition.

4. Are there any approved abuse-deterrent versions of EMBEDA?
As of this time, no abuse-deterrent reformulation of EMBEDA is marketed; efforts have focused on other formulations.

5. What is the outlook for EMBEDA’s use in future pain management?
Use is expected to decline due to regulatory restrictions, legal issues, and rising popularity of non-opioid alternatives.

References

1. Centers for Disease Control and Prevention (CDC). (2021). Pain prevalence data.
2. Food and Drug Administration (FDA). (2014). REMS for extended-release opioid products.
3. Purdue Pharma. (2019). Bankruptcy filings and legal disclosures.
4. IQVIA. (2022). US prescription opioid sales data.
5. Statista. (2022). Market share of opioid analgesics in the US.